Pharmaceuticals and Biotech Press Releases

3 ISCT Leaders Recognized as Global Cell and Gene Therapy Influencers

3 ISCT Leaders Recognized as Global Cell and Gene Therapy Influencers

​​​​​​​​​Every year, The Medicine Maker, a leading, global publication in cell and gene therapy, lists the world’s top 100 thought leaders and opinion shapers who have carried out life-changing work in the biopharmaceutical industry, helping thousands of people across the…

Bridge Therapeutics Announces the Addition of Edward J. Minskoff to Its Board of Directors

Bridge Therapeutics Announces the Addition of Edward J. Minskoff to Its Board of Directors

​Bridge Therapeutics, an innovative startup pharmaceutical company developing a practical and safe therapy for chronic pain, is pleased to announce the addition of Edward J. Minskoff to its board of directors. As a major Manhattan real estate acquirer and developer of 40…

The Bloc Elevates Jennifer Matthews to CEO and President

The Bloc Elevates Jennifer Matthews to CEO and President

​​​The Bloc, one of the largest independent health creative agencies, is proud to announce the promotion of Jennifer Matthews to CEO and president. Founding partners Susan Miller Viray and Rico Viray will assume the respective positions of chairman of The…

The National Centre for Research and Development Awards Orion Biotechnology With a Grant to Progress Development of a Treatment for Advanced Colorectal Cancer

The National Centre for Research and Development Awards Orion Biotechnology With a Grant to Progress Development of a Treatment for Advanced Colorectal Cancer

​Orion Biotechnology Canada Ltd., a developer of novel medical treatments, today announced that its European subsidiary Orion Biotechnology Polska Sp. z.o.o. was awarded a grant of just under two million U.S. dollars by the Polish National Centre for Research and Development (NCBR). The grant…

Azzur Group Announces Two New Executive Leadership Roles

Azzur Group Announces Two New Executive Leadership Roles

Azzur Group today announces the appointment of long-time Azzur veterans, Chris Mansur and Ryan Ott, to two new executive leadership roles within the organization—Chief Operating Officer and Chief Administrative Officer, respectively. These appointments come after a year of growth in…

Senator Thomas Daschle, Former Senate Majority Leader, Appointed Strategic Healthcare Advisor to Akelos Inc., Biotechnology Company Developing Opioid Drug Alternatives

Senator Thomas Daschle, Former Senate Majority Leader, Appointed Strategic Healthcare Advisor to Akelos Inc., Biotechnology Company Developing Opioid Drug Alternatives

​Akelos Inc., a biotechnology company currently developing and commercializing a novel, non-opioid anti-hyperalgesic drug to treat chronic and neuropathic pain, adds Senator Thomas Daschle to its roster of high-profile advisors. Senator Daschle provides clients with strategic public policy advice on…

Masy BioServices Acquires Metrology Laboratories Inc.

Masy BioServices today announced it has acquired Metrology Laboratories Inc. (MLI), a calibration services provider located in Rockaway, New Jersey. MLI will now be known as Masy BioServices and will continue to work from the office located at 24 Norman Road,…

Genomes.io Joins Tachyon 2.0: Consensys Ventures Blockchain-Focused Accelerator

Genomes.io, the London-based startup using blockchain technology to give people ownership and control over their genomic data, arrives at the German Bundestag in Berlin for the kickoff of Tachyon 2.0 - the accelerator program run by the world-leading blockchain company Consensys Ventures.…

Orion Biotechnology to Present OB-002 in Vitro Potency Data at the 10th International AIDS Society HIV Science Meeting in Mexico City in July 2019

Orion Biotechnology to Present OB-002 in Vitro Potency Data at the 10th International AIDS Society HIV Science Meeting in Mexico City in July 2019

Orion Biotechnology Canada Ltd., today announced that it will be presenting data on the potency of OB-002, their CCR5 antagonist currently in development for HIV prevention and oncology indications, at the 10th IAS HIV Science Meeting that will be held…

Michael Levitt, PhD, a Recipient of the Nobel Prize in Chemistry, Appointed to the Scientific Advisory Board of Akelos Inc., Biotechnology Company Developing Opioid Drug Alternatives

Michael Levitt, PhD, a Recipient of the Nobel Prize in Chemistry, Appointed to the Scientific Advisory Board of Akelos Inc., Biotechnology Company Developing Opioid Drug Alternatives

​​​​​​​​Akelos Inc., a biotechnology company currently developing and commercializing a novel, non-opioid anti-hyperalgesic drug to treat chronic and neuropathic pain, adds Michael Levitt, Ph.D., of  Stanford University , to its roster of high-profile advisors. Dr. Levitt is a biophysicist and…

Therigy to Present Ground-Breaking Health System Specialty Pharmacy Quality Initiative at AMCP Managed Care and Specialty Pharmacy 2019 Annual Meeting

Therigy, the trusted source for specialty pharmacy technology, consulting and outcomes, announced today that the company will present a poster from its recently completed quality initiative: “Improving Quality of Care in Rheumatoid Arthritis (RA) Utilizing Hospital-Based Specialty Pharmacies in Monitoring…

Leading Bio-Tech Firm Alpha Genesis Blocks College Scam-Like Applicants

Leading Bio-Tech Firm Alpha Genesis Blocks College Scam-Like Applicants

The Alpha Genesis Primate Research Center's careful review and high standards for summer internship applicants have likely prevented the Company from admitting unqualified students from wealthy families into its elite summer programs, according to Company Management. Prosecutors have charged dozens of…

Accelerating Development of Non-Opioid Pain Medicines – American Pain Society's Conference on Analgesic Trials (APS-CAT)

Dr. Neil Singla, Chief Executive Officer of Lotus Clinical Research, will chair the 4th annual American Pain Society Conference on Analgesic Trials on Wednesday, April 3, 2019 in Milwaukee, Wisconsin. The theme of this year’s APS-CAT is Accelerating Development of Non-Opioid Pain…

Marizyme Signs LOI With Chromocell to Acquire or License Assets

Marizyme Signs LOI With Chromocell to Acquire or License Assets

Marizyme, Inc. (“Marizyme” or the “Company”), a publicly traded (OTC: MRZM) company focusing on acquiring late-stage drug assets for use in the acute care space and related areas, announced today that they signed a Letter of Intent to evaluate the licensing…

Marizyme, Inc. Receives FDA Feedback on Development Plan for Krillase™ in Pediatric Stroke

Marizyme, Inc. Receives FDA Feedback on Development Plan for Krillase™ in Pediatric Stroke

Marizyme, Inc. (“Marizyme” or the “Company”), a publicly traded (OTC: MRZM) company focusing on acquiring late-stage drug assets for use in the acute care space for development and commercialization, announced today that they have received FDA feedback regarding their development plan…

A New Model for Heart Valve Disease Drug Discovery

A New Model for Heart Valve Disease Drug Discovery

An article published in Experimental Biology and Medicine (Volume 244, Issue 3, February, 2019) (https://journals.sagepub.com/doi/pdf/10.1177/1535370219829006) describes a new model for heart valve physiology. The study, led by Dr. Carla Lacerda, from the Department of Chemical Engineering at Texas Tech University…

Migraine Treatment Made Possible With 'Migraine Cut' Spray

Migraine Treatment Made Possible With 'Migraine Cut' Spray

A group of researchers at MIM Daroo Pharmaceutical Company have managed to produce a spray called "Migraine Cut" which can treat migraine headaches. Migraine treatment is among important issues that have remained very complicated in the world of medicine. The…

Glauconix Biosciences Completes Pilot Study Using Nemus Biosciences' Bioengineered Cannabinoid-Based Compound for Glaucoma Treatment

Glauconix Biosciences Completes Pilot Study Using Nemus Biosciences' Bioengineered Cannabinoid-Based Compound for Glaucoma Treatment

Glauconix Biosciences Inc., a specialty pharmaceutical company that uses its patented platform technology to develop human 3D ocular tissues that mimic the fluid dynamics in the eye to expedite and de-risk the R&D of ophthalmic treatments while reducing development costs, announced…

Robert Benson, PhD, Appointed Intellectual Property Advisor to Akelos Inc., Biotechnology Company Developing Opioid Drug Alternatives

Robert Benson, PhD, Appointed Intellectual Property Advisor to Akelos Inc., Biotechnology Company Developing Opioid Drug Alternatives

​​Akelos Inc., a biotechnology company currently developing and commercializing a novel, non-opioid anti-hyperalgesic drug to treat chronic and neuropathic pain adds Robert Benson, Ph.D., formerly of Harvard University and the National Institutes of Health, to its roster of high-profile advisors.…

Almac Group Announces Almac One™ – a Unified Clinical Trial Supply Solution

Almac Group Announces Almac One™ – a Unified Clinical Trial Supply Solution

Almac Group announces Almac One™ - providing the first unified Clinical Trial Supply solution. This solution redefines the Clinical Supply Chain experience, creating a responsive end-to-end process that enhances visibility and accuracy throughout the lifecycle of a clinical study.  The…

Login

Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Or form here

Already have an account ? Login

Reset Password

Already have an account ? Login